WuXi AppTec(SH:603259) Huafu Securities·2025-12-28 11:20Investment Rating - The report maintains an "Outperform" rating for the industry [7] Core Insights - The year 2026 is expected to be a significant year for IO combined with ADC, with China leading the development of second-generation IO combined ADC therapies [5][24] - The immune therapy and ADC have a natural complementarity, enhancing efficacy and expanding the beneficiary population [17] - The report highlights the importance of innovative drugs, medical devices, and the focus on domestic demand in the pharmaceutical sector [5][48] Summary by Sections 1. IO+ADC: 2026 Catalyst Year - PD-1 combined with ADC has shown promising results in first-line NSCLC, with a global phase III trial expected to report results in 2026 [1.1][27] - Second-generation IO combined with ADC is progressing, with several global phase III studies initiated [1.2][39] 2. Weekly Market Review and Hotspot Tracking (Dec 22-26, 2025) - The CITIC Pharmaceutical Index fell by 0.2%, underperforming the CSI 300 Index by 2.1 percentage points [4][48] - The report notes a general decline in the pharmaceutical sector, with specific stocks like Hongyuan Pharmaceutical and Luyuan Pharmaceutical showing significant gains [4][63] 3. Investment Focus - The report suggests focusing on innovative drugs with commercial capabilities, potential blockbuster candidates, and cutting-edge technologies such as gene therapy and CAR-T [5][48] - Medical devices are highlighted as a sector with growth potential, particularly in areas like endoscopy and robotics [5][48]